Insulet Corporation (NASDAQ:PODD) Given Consensus Rating of “Moderate Buy” by Brokerages

Insulet Corporation (NASDAQ:PODD) has received an average recommendation of “Moderate Buy” from the twenty-four analysts that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, five have issued a hold rating and eighteen have given a buy rating to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is $327.2381.

Several research firms recently commented on PODD. Stifel Nicolaus reduced their target price on Insulet from $370.00 to $350.00 and set a “buy” rating for the company in a research report on Wednesday, February 4th. Evercore reduced their target price on Insulet from $340.00 to $240.00 and set an “outperform” rating for the company in a research report on Monday, April 6th. Barclays restated an “underweight” rating and set a $286.00 target price on shares of Insulet in a research report on Thursday, February 19th. The Goldman Sachs Group reduced their target price on Insulet from $326.00 to $277.00 and set a “buy” rating for the company in a research report on Wednesday, April 8th. Finally, BTIG Research reduced their target price on Insulet from $380.00 to $320.00 and set a “buy” rating for the company in a research report on Monday, April 13th.

Insider Transactions at Insulet

In other news, Director Michael R. Minogue purchased 2,030 shares of the company’s stock in a transaction on Wednesday, February 25th. The stock was purchased at an average price of $246.23 per share, with a total value of $499,846.90. Following the completion of the purchase, the director directly owned 17,483 shares in the company, valued at approximately $4,304,839.09. This trade represents a 13.14% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 0.36% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Insulet

Several hedge funds have recently added to or reduced their stakes in the company. Diversify Wealth Management LLC lifted its stake in Insulet by 61.1% during the first quarter. Diversify Wealth Management LLC now owns 8,228 shares of the medical instruments supplier’s stock worth $1,727,000 after purchasing an additional 3,120 shares during the last quarter. Cullinan Associates Inc. bought a new stake in Insulet during the first quarter worth about $525,000. Citizens Financial Group Inc. RI lifted its stake in Insulet by 35.8% during the first quarter. Citizens Financial Group Inc. RI now owns 2,554 shares of the medical instruments supplier’s stock worth $536,000 after purchasing an additional 673 shares during the last quarter. Fifth Third Bancorp lifted its stake in Insulet by 170.6% during the first quarter. Fifth Third Bancorp now owns 23,228 shares of the medical instruments supplier’s stock worth $4,874,000 after purchasing an additional 14,644 shares during the last quarter. Finally, American Trust lifted its stake in Insulet by 8.6% during the first quarter. American Trust now owns 1,180 shares of the medical instruments supplier’s stock worth $248,000 after purchasing an additional 93 shares during the last quarter.

Insulet Price Performance

Insulet stock opened at $175.04 on Friday. Insulet has a 52 week low of $158.35 and a 52 week high of $354.88. The business has a 50-day simple moving average of $216.37 and a 200 day simple moving average of $267.50. The company has a quick ratio of 2.15, a current ratio of 2.81 and a debt-to-equity ratio of 0.61. The stock has a market cap of $12.12 billion, a price-to-earnings ratio of 50.01, a PEG ratio of 1.05 and a beta of 1.20.

Insulet (NASDAQ:PODD) last posted its earnings results on Wednesday, February 18th. The medical instruments supplier reported $1.55 EPS for the quarter, topping the consensus estimate of $1.48 by $0.07. Insulet had a return on equity of 24.90% and a net margin of 9.12%.The business had revenue of $783.80 million during the quarter, compared to analysts’ expectations of $768.31 million. During the same period in the previous year, the business earned $1.15 earnings per share. The firm’s revenue was up 31.2% on a year-over-year basis. On average, research analysts forecast that Insulet will post 6.27 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.